Table 3.
Univariate Cox Regression Analyses Results for Survival
| Hazard Ratio (95% CI)* | p Value | |
|---|---|---|
| Age | 0.98 (0.95–1.01) | 0.258 |
| Gender | ||
| Men | 1.00* | |
| Women | 0.56 (0.21–1.48) | 0.240 |
| Smoking | ||
| No | 1.00* | |
| Yes | 0.83 (0.33–2.08) | 0.696 |
| Pack/years | 1.01 (1.00–1.03) | 0.012 |
| Comorbidity | ||
| No | 1.00* | |
| Yes | 2.36 (0.71–7.89) | 0.162 |
| Histological type | ||
| NOS | 1.00* | |
| Adenocarcinoma | 0.99 (0.11–8.98) | 0.996 |
| Squamous cell carcinoma | 1.46 (0.19–10.91) | 0.715 |
| Differentiation (n = 44) | ||
| Low | 1.00* | |
| Moderate | 0.50 (0.15–1.67) | 0.262 |
| EGFR (n = 34) | ||
| No | 1.00* | |
| Yes | 0.11 (0.01–1.00) | 0.049 |
| Performance status | ||
| 0–1 | 1.00* | |
| ≥2 | 5.97 (2.05–17.35) | 0.001 |
| Stage | ||
| IIIB | 1.00* | |
| IV | 1.90 (0.45–8.07) | 0.382 |
| Duration of treatment with erlotinib (days) | 0.48 (0.33–0.69) | <0.001 |
| Treatment line | ||
| First | 1.00* | |
| Second | 0.98 (0.41–2.37) | 0.967 |
| Third–fourth | 0.54 (0.18–1.65) | 0.279 |
| Rash | ||
| No | 1.00* | |
| Yes | 0.06 (0.01–0.24) | <0.001 |
| Rash grade | ||
| I | 1.00* | |
| II/III | 1.36 (0.09–21.81) | 0.826 |
| Time to rash (days) | 0.97 (0.87–1.09) | 0.639 |
*
Reference category.